These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21546220)

  • 21. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
    Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
    Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
    Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels.
    Grambaite R; Stenset V; Reinvang I; Walhovd KB; Fjell AM; Fladby T
    J Int Neuropsychol Soc; 2010 Jan; 16(1):58-69. PubMed ID: 19835655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid beta 1-42 in cerebrospinal fluid is associated with cognitive plasticity.
    Uttner I; Schurig N; von Arnim CA; Lange-Asschenfeldt C; Brettschneider J; Riepe MW; Tumani H
    Psychiatry Res; 2011 Nov; 190(1):132-6. PubMed ID: 21620485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.
    de Souza LC; Chupin M; Lamari F; Jardel C; Leclercq D; Colliot O; Lehéricy S; Dubois B; Sarazin M
    Neurobiol Aging; 2012 Jul; 33(7):1253-7. PubMed ID: 21489655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels.
    Arenaza-Urquijo EM; Molinuevo JL; Sala-Llonch R; Solé-Padullés C; Balasa M; Bosch B; Olives J; Antonell A; Lladó A; Sánchez-Valle R; Rami L; Bartrés-Faz D
    J Alzheimers Dis; 2013; 35(4):715-26. PubMed ID: 23481686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
    Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E
    Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
    Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P
    Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
    Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
    Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
    Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
    Kang K; Ko PW; Jin M; Suk K; Lee HW
    J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.